Pharmacokinetics of high-dose busulphan in relation to age and chronopharmacology
- PMID: 2060084
- DOI: 10.1007/BF00689702
Pharmacokinetics of high-dose busulphan in relation to age and chronopharmacology
Abstract
Busulphan levels in plasma were measured in 27 patients during conditioning therapy (1 mg/kg x 4 for 4 days) before bone marrow transplantation. The mean minimal concentration found in children aged less than 5 years (237 ng ml-1) was lower than that observed in adults or older children (607 and 573 ng ml-1, respectively). The AUC for the last dose was significantly lower in young children (2.315 h ng ml-1) than in adults or older children (6,134 and 5,937 h ng ml-1, respectively). The elimination half-life for the last dose in young children was shorter (2.05 h) than that in either adults (2.59 h) or older children (2.79 h). When the AUC was normalized for body surface area, the difference between young children and the other groups was smaller but remained statistically significant. The total body clearance was significantly higher in young children (7.3 ml min-1 kg-1) as compared with both older children and adults (3.02 and 2.7 ml min-1 kg-1, respectively). The plasma levels of busulphan showed circadian rhythmicity, especially in young children. The concentration measured during the night in some patients was up to 3-fold that observed during daytime. We conclude that the busulphan dosage for children must be reconsidered and that further studies are urgently needed to develop an optimal therapy.
Similar articles
-
Influence of prophylactic anticonvulsant therapy on high-dose busulphan kinetics.Cancer Chemother Pharmacol. 1993;33(3):181-6. doi: 10.1007/BF00686213. Cancer Chemother Pharmacol. 1993. PMID: 8269597
-
A phase II trial of liposomal busulphan as an intravenous myeloablative agent prior to stem cell transplantation: 500 mg/m(2) as a optimal total dose for conditioning.Bone Marrow Transplant. 2002 Dec;30(12):833-41. doi: 10.1038/sj.bmt.1703739. Bone Marrow Transplant. 2002. PMID: 12476274 Clinical Trial.
-
Busulphan kinetics and limited sampling model in children with leukemia and inherited disorders.Bone Marrow Transplant. 1996 Nov;18(5):843-50. Bone Marrow Transplant. 1996. PMID: 8932835
-
Aspects concerning busulfan pharmacokinetics and bioavailability.Leuk Lymphoma. 1996 Aug;22(5-6):395-407. doi: 10.3109/10428199609054777. Leuk Lymphoma. 1996. PMID: 8882952 Review.
-
Pharmacologically-guided dose adjustment of busulfan in high-dose chemotherapy regimens: rationale and pitfalls (review).Anticancer Res. 1994 Nov-Dec;14(6A):2363-70. Anticancer Res. 1994. PMID: 7825973 Review.
Cited by
-
Pharmacokinetics study of once-daily intravenous busulfan in conditioning regimens for hematopoietic stem cell transplantation.Int J Hematol. 2015 May;101(5):497-504. doi: 10.1007/s12185-015-1756-6. Epub 2015 Feb 12. Int J Hematol. 2015. PMID: 25672602
-
Oral chemotherapy agents in the treatment of leukaemia.Drugs. 1999;58 Suppl 3:109-18. doi: 10.2165/00003495-199958003-00015. Drugs. 1999. PMID: 10711849 Review.
-
Influence of prophylactic anticonvulsant therapy on high-dose busulphan kinetics.Cancer Chemother Pharmacol. 1993;33(3):181-6. doi: 10.1007/BF00686213. Cancer Chemother Pharmacol. 1993. PMID: 8269597
-
Formulation and stability of busulfan for intravenous administration in high-dose chemotherapy.Cancer Chemother Pharmacol. 1996;37(5):401-8. doi: 10.1007/s002800050404. Cancer Chemother Pharmacol. 1996. PMID: 8599861
-
The role of busulfan in bone marrow transplantation.Med Oncol. 1999 Sep;16(3):166-76. doi: 10.1007/BF02906128. Med Oncol. 1999. PMID: 10523796 Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical
Miscellaneous